Target intelligence / Profile preview

BCAN antisense RNA 1 (BCAN-AS1)

Target: BCAN-AS1
Molecular classification: Long non-coding RNA (lncRNA), Antisense RNA, Non-coding RNA

Overview

BCAN antisense RNA 1 (BCAN-AS1) is a long non-coding antisense transcript implicated in oncogenesis, particularly in pancreatic ductal adenocarcinoma. Mechanistically, BCAN-AS1 acts as a scaffold that stabilizes the c-Myc protein by facilitating its interaction with SNIP1 and preventing SKP2-mediated c-Myc ubiquitination and degradation. BCAN-AS1 overexpression is associated with increased tumor aggressiveness and poor prognosis. Knockdown of BCAN-AS1 using antisense oligonucleotides suppresses tumor growth and metastasis in model systems, suggesting therapeutic potential for cancers with high BCAN-AS1 expression.

Other names: RP11-284F21.9lncRNA BCAN-AS1

Mechanism of action

Antisense oligonucleotide inhibition leads to reduced BCAN-AS1 RNA levels, thereby destabilizing c-Myc protein and inhibiting tumor growth and metastasis

Biological functions

Regulation of gene expression (notably c-Myc stabilization)Promoting malignant phenotypesModulation of protein ubiquitination and degradation (by blocking SKP2-mediated c-Myc ubiquitination)Acting as a molecular scaffold

Disease associations

Cancer, specifically pancreatic ductal adenocarcinoma (PDAC)Associated with poor prognosis in cancerAlso linked to other cancers such as lung cancer and cervical cancer (per associative databases)

Safety considerations

No direct safety concerns reported; general challenges apply to targeting lncRNAs, including delivery and potential off-target effects

Interacting drugs

Antisense oligonucleotide targeting BCAN-AS1

Biomarkers

BCAN-AS1 expression level (prognostic marker for poor outcome in PDAC and possibly other cancers)

Beyond the preview

Go deeper on BCAN antisense RNA 1 (BCAN-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCAN antisense RNA 1 (BCAN-AS1).

Explore the full profile